Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of EUS-Guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)

NCT03033225 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03033225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03033225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of EUS-Guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2017
Completion date
September 20, 2023
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic carcinoma, locally advanced pancreatic carcinoma, metastatic pancreatic carcinoma, pancreatic neoplasm, stage ii pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable pancreatic carcinoma